Corcept Therapeutics Inc logo

CORT - Corcept Therapeutics Inc News Story

$17.44 -0.3  -1.9%

Last Trade - 9:00pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.59bn
Enterprise Value £1.27bn
Revenue £271.3m
Position in Universe 1834th / 6436

BRIEF-Corcept Therapeutics Initiates Second Phase 2 Trial Of Miricorilant To Treat Weight Gain Caused By Antipsychotic Medication

Thu 10th September, 2020 2:34pm
Sept 10 (Reuters) - Corcept Therapeutics Inc  CORT.O :
    * CORCEPT THERAPEUTICS INITIATES SECOND PHASE 2 TRIAL OF
MIRICORILANT  TO TREAT WEIGHT GAIN CAUSED BY ANTIPSYCHOTIC
MEDICATION

Source text for Eikon:  ID:nGNXbPx2kK 
Further company coverage:  CORT.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.